1st, thanxx for this forum. I found you guys right on time.
I'm not yet a user but I'm a bit familiar with the NextGen technologies from a concept perspective but for sure not from a user perspective.
However, I am in a new situation where I may have access to a financial support for a NextGen platform. But I want to understand if the work being made at our institution could really make use of a NextGen instrument. Then I may like to talk about the advantages of 454, Solexa and SOLID.
Because I'm in a Biomedical environment, most work being done here is resequencing, and is targeting a single gene, or a group of genes (disease associated...). To make it short, let's say that we may need to sequence 1 to 10 genes and small virus genomes (<100kb), something some of you may find small numbers, but for large cohort of patients. Even with Biomeks and CEquencers you know how much efforts it takes.
From what I have read in the 'industry' litterature, the NextGen instruments have not been defined for such projects. Am I right? They are more into large, large, large pieces sequencing for a single sample.
I understand the Roche PicoPlate can be divided into 16 runs (16 patients?) and I rapidly read this morning about their new Ligation Multiplex Identifier (MID) kit that may increase that number.
But are the Solexa and Solid approach compatible with such sequencing strategy for small number of genes? and for multiple sample runs?
Maybe I should stick with CEquencing?
I'm not yet a user but I'm a bit familiar with the NextGen technologies from a concept perspective but for sure not from a user perspective.
However, I am in a new situation where I may have access to a financial support for a NextGen platform. But I want to understand if the work being made at our institution could really make use of a NextGen instrument. Then I may like to talk about the advantages of 454, Solexa and SOLID.
Because I'm in a Biomedical environment, most work being done here is resequencing, and is targeting a single gene, or a group of genes (disease associated...). To make it short, let's say that we may need to sequence 1 to 10 genes and small virus genomes (<100kb), something some of you may find small numbers, but for large cohort of patients. Even with Biomeks and CEquencers you know how much efforts it takes.
From what I have read in the 'industry' litterature, the NextGen instruments have not been defined for such projects. Am I right? They are more into large, large, large pieces sequencing for a single sample.
I understand the Roche PicoPlate can be divided into 16 runs (16 patients?) and I rapidly read this morning about their new Ligation Multiplex Identifier (MID) kit that may increase that number.
But are the Solexa and Solid approach compatible with such sequencing strategy for small number of genes? and for multiple sample runs?
Maybe I should stick with CEquencing?
Comment